Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia

Date

2021

Authors

Kelliny, S.
Xiong, J.
Bobrovskaya, L.
Zhou, X.F.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Neurotoxicity Research, 2021; 39(6):1689-1707

Statement of Responsibility

Sally Kelliny, Jing Xiong, Larisa Bobrovskaya and Xin-Fu Zhou

Conference Name

Abstract

Oxidative stress is a key factor in the pathogenesis of several neurodegenerative disorders and is involved in the accumulation of amyloid beta plaques and Tau inclusions. Edaravone (EDR) is a free radical scavenger that is approved for motor neuron disease and acute ischemic stroke. EDR alleviates pathologies and cognitive impairment of AD via targeting multiple key pathways in transgenic mice. Herein, we aimed to study the effect of EDR on Tau pathology in P301L mice; an animal model of frontotemporal dementia (FTD), at two age time points representing the early and late stages of the disease. A novel EDR formulation was utilized in the study and the drug was delivered orally in drinking water for 3 months. Then, behavioral tests were conducted followed by animal sacrifice and brain dissection. Treatment with EDR improved the reference memory and accuracy in the probe trial as evaluated in Morris water maze, as well as novel object recognition and significantly alleviated motor deficits in these mice. EDR also reduced the levels of 4-hydroxy-2-nonenal and 3-nitrotyrosine adducts. In addition, immunohistochemistry showed that EDR reduced tau phosphorylation and neuroinflammation and partially rescued neurons against oxidative neurotoxicity. Moreover, EDR attenuated downstream pathologies involved in Tau hyperphosphorylation. These results suggest that EDR may be a potential therapeutic agent for the treatment of FTD.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2021, The Author(s), under exclusive licence to Springer Science Business Media, LLC, part of Springer Nature

License

Call number

Persistent link to this record